Alphatec Hlds

Alphatec Holdings, Inc. engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings. The company was founded on March 4, 2005 and is headquartered in Carlsbad, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Alphatec (ATEC) reports stellar Q1 growth and strategic acquisitions

Alphatec (ATEC) showcased robust revenue growth, strategic acquisitions, and a focus on enhancing procedural efficiency and surgeon adoption.
While challenges exist in achieving EBITDA break-even and expanding margins, ATEC's strong performance and growth outlook present promising opportunities.
The company's emphasis on technology integration, international expansion, and increasing robotics utilization positions ATEC for future success.

Alphatec (ATEC) reports robust Q2 growth and eyes international expansion

Alphatec's Q2 performance reflects strong revenue growth, margin expansion, and market share gains driven by strategic initiatives in spine surgery. The company's focus on innovation, surgeon adoption, and geographic expansion positions it well for future growth and success in the spine market.

Alphatec (ATEC) reports robust Q3 earnings, eyes growth opportunities

Alphatec (ATEC) delivered strong financial performance in Q3 2023, driven by revenue growth, positive adjusted EBITDA, and strategic initiatives.
The company's strengths lie in its spine surgery focus, new product launches, and advancements in informatics and robotic integration.
Challenges include managing risks, balancing growth with profitability, and navigating market disruptions, while opportunities exist in expansion and technology integration.

Alphatec (ATEC) reports robust Q4 performance, eyes international expansion

Alphatec (ATEC) had a strong Q4 2023, focusing on clinical excellence and market share growth. Challenges include managing debt and sustaining momentum. Opportunities lie in international expansion and innovative product launches.

Alphatec Hlds (ATEC) reports robust Q1 performance and growth outlook

Alphatec Hlds (ATEC) delivered a strong Q1 2024 performance with significant revenue growth, surgeon adoption, and sales team confidence, underpinned by a focus on innovation and market expansion.
While facing challenges in debt management and profitability, the company's strategic outlook, financial strength, and growth drivers position it well for future success and sustained growth.
By capitalizing on opportunities in technology integration, international expansion, and market share expansion, Alphatec is poised to drive continued innovation and value creation in the spine surgery market.

Alphatec Hlds (ATEC) reports robust Q2 growth and eyes Japan expansion

Alphatec Hlds (ATEC) delivered strong financial results in Q2 2024, showcasing growth in revenue, profitability, and surgeon engagement, while focusing on innovation and clinical distinction.
The company faces challenges in achieving cash flow break-even, entering new markets like Japan, and expanding into deformity surgery, but sees opportunities in market growth and technological advancements.
Overall, Alphatec Hlds (ATEC) remains committed to advancing spine surgery through technology, attracting surgeons to advanced tools, and driving sustainable growth through strategic initiatives.

Alphatec (ATEC) excels in Q3 earnings, eyes growth opportunities

Alphatec (ATEC) reported a robust Q3 performance marked by strong revenue growth and positive adjusted EBITDA, driven by surgical and EOS revenue increases. While challenges in gross margin and cash flow breakeven exist, the company remains optimistic about long-term financial commitments and revenue growth. ATEC's strategic focus on value creation, surgeon adoption, and innovation positions it well for future success.

Alphatec Hlds (ATEC) reports strong growth and strategic expansion plans

Alphatec Hlds (ATEC) delivered robust financial performance in Q4 2024 and full year 2024, showcasing strong revenue growth and profitability. The company's strategic strengths lie in its growth profile, investment thesis, and market expansion initiatives, positioning it for sustained success. While facing challenges such as industry disruption and competition, Alphatec Hlds (ATEC) has opportunities to capitalize on market trends, international expansion, and product portfolio enhancements.

Alphatec (ATEC) reports strong Q1 results, eyes growth opportunities

Alphatec (ATEC) demonstrated robust financial performance in Q1 2025, driven by revenue and surgical growth, improved EBITDA margin, and enhanced cash flow. The company's strategic focus on clinical excellence, innovative technology adoption, and commitment to spine specialization are key strengths. Challenges lie in market reach limitations, competitive pressures, and the need for sustained operational efficiency. Opportunities include significant revenue growth potential, market expansion through technology adoption, and differentiation through procedural solutions.

Alphatec Holdings (ATEC) excels in Q2 2025, poised for growth

Alphatec Holdings (ATEC) demonstrated robust financial performance in Q2 2025, marked by strong revenue growth, record EBITDA, and positive free cash flow, underpinned by operational efficiency and strategic focus. With a solid cash position, focus on innovation, and plans for market expansion through new procedures and technology, ATEC is well-positioned for future growth and profitability. While challenges exist in maintaining growth and managing costs, ATEC's strategic initiatives, including robotics launch and surgeon adoption drive, present promising opportunities for sustained success.

Alphatec (ATEC) reports stellar Q3 results, eyes growth in spine innovation

Alphatec (ATEC) demonstrated strong financial performance in Q3, driven by revenue growth, improved margins, and operational efficiency. The company's focus on innovation, proceduralization, and market expansion positions it well for future growth and competitive advantage. While ATEC faces challenges in maintaining growth and profitability targets, strategic initiatives and market opportunities offer avenues for sustained success.

Alphatec (ATEC) posts robust Q4 results, eyes growth in spine market

Alphatec (ATEC) delivered strong Q4 2025 results, showcasing revenue growth, improved EBITDA, and a solid cash position, underpinned by surgical revenue expansion. While facing challenges such as rising expenses, the company's focus on innovation and market leadership in key segments provides a strong foundation for growth. Looking ahead, ATEC's optimistic 2026 outlook and increased EBITDA guidance signal opportunities for continued success and market expansion.